India Pharma Outlook Team | Wednesday, 24 December 2025
Emcure Pharmaceuticals has announced a nationwide rollout of its obesity drug Poviztra, marking a focused push into India’s expanding weight-management market. The company plans to move beyond a metro-centric strategy and build demand across Tier II, Tier III cities and smaller towns by using its established domestic distribution network.
Poviztra is a semaglutide-based therapy belonging to the glucagon-like peptide-1 (GLP-1) receptor agonist class, widely used for chronic weight management. The product is being marketed in India through a partnership with Novo Nordisk, under which Emcure has exclusive rights for commercialisation and distribution in the country.
The drug has been priced at ?8,790 per month for the starter dose, making it around 19 per cent cheaper than the comparable dose of Novo Nordisk’s Wegovy. Poviztra is available in five dosage strengths, starting from 0.25 mg and going up to a maintenance dose of 2.4 mg. It is prescribed as a once-weekly injectable and is intended to be used alongside diet control and physical activity for adults living with obesity or overweight conditions linked to metabolic disorders.
Company executives said the pricing and wider geographic focus are aimed at improving access to obesity treatment, which has largely been limited to urban centres due to high costs and low awareness. Emcure plans to work closely with physicians across regions to expand the adoption of GLP-1 therapies and address unmet medical needs beyond large cities.
The launch comes at a time when competition in India’s obesity drug segment is intensifying. Global pharmaceutical companies are increasing their presence, driven by rising obesity rates, higher diagnosis levels, and growing patient willingness to seek medical intervention. Industry estimates suggest the domestic obesity and metabolic disorder market could see sustained growth over the next decade.
Also Read: Biocon Biologics Secures Global Rights to Adalimumab Biosimilar
With Poviztra, Emcure is positioning itself to capture a larger share of this emerging market by combining competitive pricing, broad distribution reach, and a long-term focus on chronic care therapies across India.
